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Abstract  81 
Objectives 82 
In the absence of consensus, the present meta-analysis was performed to determine an 83 
optimal dosing regimen of vancomycin for neonates.  84 
Methods 85 
A “meta-model” using NONMEM with 4894 concentrations from 1631 neonates was built 86 
and Monte Carlo simulations were performed to design an optimal intermittent infusion, 87 
aiming at reaching a target AUC0-24 of 400 mg*h/L at steady state in at least 80% of 88 
neonates.  89 
Results 90 
A two-compartment model best fitted the data. Current weight, post-menstrual age (PMA) 91 
and serum creatinine were the significant covariates for clearance (CL). After model 92 
validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose 93 
(15 mg/kg twice daily if < 35 weeks PMA and 15 mg/kg three times daily if ≥ 35 weeks 94 
PMA) achieved the AUC0-24  target earlier than a standard “Blue Book” dosage regimen 95 
in more than 89% of the treated patients.  96 
Conclusions 97 
The results of a population meta-analysis of vancomycin data have been used to develop 98 
a new dosing regimen for neonatal use and assist in the design of the model-based, 99 
multinational European trial, NeoVanc.  100 
  101 
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Introduction  102 
Vancomycin is one of the most widely used antibiotics in the world for the treatment of 103 
serious Gram-positive infections. It is a high molecular weight complex glycopeptide 104 
which inhibits the cell wall synthesis of Gram-positive bacteria by the formation of stable 105 
complex murein pentapeptides, thereby causing inhibition of further peptidoglycan 106 
formation. It became the treatment of choice for staphylococcal infections, when 107 
staphylococcal strains developed resistance to treatment with penicillin. It was then 108 
replaced by methicillin in the 1960s, but when the incidence of late onset neonatal sepsis 109 
increased due to coagulase negative and methicillin-resistant staphylococci, the use of 110 
vancomycin re-emerged and it is today the treatment of choice for many staphylococcal 111 
infections.1,2  112 
According to recent surveys,3-7 neonatal dosage recommendations for vancomycin are 113 
highly variable, and include a range of single or multiple clinical factors, such as 114 
gestational age (GA), post-natal age (PNA), postmenstrual age (PMA), weight and 115 
creatinine clearance. Even internationally recognised dosing guidelines gave different 116 
dosing recommendations, either as continuous (CVA) or intermittent intravenous (IVA) 117 
vancomycin administration. However, although vancomycin is one of the most studied 118 
antibiotics in neonates,2,8-10 population pharmacokinetic (popPK) and pharmacokinetic–119 
pharmacodynamic (popPKPD) approaches have had limited success in leading to a clear 120 
consensus on the optimal dosing regimen to use in routine clinical practice. This is partly 121 
because the models and results are dependent on study / centre-related factors, including 122 
differences in the covariates that were incorporated in the final analysis. The present 123 
study aimed to conduct a meta-analysis of published individual pharmacokinetic data and 124 
to build a popPKPD model that would take into account all available variables, as part of 125 
the programme of work to plan the NeoVanc trial.11  126 
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 128 
Methods  129 
Identification of  individual patient data 130 
Published PK or PK/PD studies were identified through databases (PubMed, Embase) 131 
in 2014, according to the following screening criteria (PK study, vancomycin, neonates 132 
and infants,114 single and multicentre studies, all countries. The investigator 133 
responsible for the publication was contacted, invited to participate in the present study 134 
and provided individual vancomycin dose and concentration data and associated 135 
covariates.  Additional, non-published, routine Therapeutic Drug Monitoring (TDM) data 136 
from our center (hospital Robert Debré – Paris – France) were also used. All data were 137 
anonymised before transfer with a pre-defined data sharing agreement, according to 138 
Good Clinical and Laboratory Practices.    139 
  140 
Requested covariates and individual information 141 
The following dataset of mandatory variables was collected to ensure that individual 142 
patient data could be included in the pooled model.  143 
Vancomycin administration information:  dosing history for each infant (time of start of 144 
infusion, time of end of infusion and doses), continuous or intermittent infusion, 145 
vancomycin concentrations and exact sampling day and time.  146 
Demographic covariates: gestational age, postnatal age, birth weight, current weight (at 147 
sampling), gender.  148 
Information on co-medications was not collected and not analysed as it was available in 149 
only a limited number of neonates.  150 
Biological covariates: serum creatinine concentrations 151 
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Study-related covariates: analytical method used to quantify vancomycin (FPIA EMIT, 152 
PENTINIA or CMIA CLIA), creatinine assay method (Jaffé or enzymatic) and 153 
corresponding units. 154 
Data analysis 155 
PK data were made available on a standard Microsoft Office Excel spreadsheet (CIC, 156 
1426, Hôpital Robert Debré) and formatted for subsequent modelling using NONMEM V 157 
7.2 (Icon Development Solutions, USA).  158 
A first order conditional estimation (FOCE) method with interaction was used to estimate 159 
PK parameters and their variability. One and two compartment models with first order 160 
elimination were tested to estimate clearance (CL), central volume of distribution (V1), 161 
peripheral volume of distribution (V2) and intercompartmental clearance (Q) using the 162 
appropriate ADVAN subroutines. Inter-individual variability of the pharmacokinetic 163 
parameters was best described with an exponential model and was expressed as θ i= 164 
θmean*eηi, where θi represents the parameter value of the ith subject, θmean the typical value 165 
of the parameter in the population and ηi the variability between subjects, which is 166 
assumed to follow a normal distribution with a mean of zero and variance ω2.  167 
Covariate analysis followed a forward and backward selection process. The likelihood 168 
ratio test was used to test the effect of each variable on model parameters. The effects 169 
of current weight, gestational age, postnatal age, postmenstrual age, serum creatinine 170 
concentration, analytical methods of vancomycin and creatinine, and ethnicity were 171 
investigated as potential covariates affecting PK parameters. During the first step of 172 
covariate model building, a covariate was included if a significant (p<0.05, 2 distribution 173 
with one degree of freedom) decrease (reduction>3.84) in the objective function value 174 
(OFV) from the basic model was obtained. All the significant covariates were then added 175 
simultaneously into a ‘full’ model. Subsequently, each covariate was independently 176 
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removed from the full model. If the increase in the OFV was higher than 6.635 (p<0.01, 177 
2 distribution), the covariate was retained in the final model. 178 
Model validation was based on graphical and statistical criteria. Goodness-of-fit plots, 179 
including observed (DV) versus population prediction (PRED); DV versus individual 180 
prediction (IPRED); conditional weighted residuals (CWRES) versus time and CWRES 181 
versus PRED were initially used for diagnostic purposes. The stability and performance 182 
of the final model was also assessed by means of a nonparametric bootstrap with re-183 
sampling and replacement. Re-sampling was repeated 200 times and the values of 184 
estimated parameters from the bootstrap procedure were compared with those estimated 185 
from the original data set. The entire procedure was performed in an automated fashion, 186 
using Perl-speaks-Nonmem (PsN v2.30). The final model was also evaluated graphically 187 
and statistically by normalised prediction distribution errors (NPDE). One thousand 188 
datasets were simulated using the final population model parameters. NPDE results were 189 
summarized graphically by default as provided by the NPDE R package (v1.2): (i) QQ-190 
plot of the NPDE; (ii) histogram of the NPDE. The NPDE is expected to follow the N (0, 191 
1) distribution.12 192 
Monte Carlo simulations for dosage optimisation were performed to evaluate different 193 
weight adjusted (mg/kg) dosing regimens for three predefined neonatal groups: 194 
postmenstrual age (PMA) <29, 29-35 and >35 weeks. Drug exposure was simulated 100 195 
times for each set of patients including only the Caucasian patients. Area under the curve 196 
between 0 and 24h on the first treatment day (AUC0-24h) and AUC24h at steady state 197 
(AUCSS-24h) were calculated for each simulated patient. The parameter estimates obtained 198 
from the final model were used to estimate the target attainment rate for an AUC24h of 199 
≥400 mg*h/L with the standard dosage regimen recommended in the “Blue Book” 13 and 200 
to define the optimal dosing regimen able to attain this target in 80% of patients. The 201 
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current dosage recommendations and a loading dose followed by a maintenance dose 202 
administered as an intermittent infusion were evaluated in the 3 PMA groups.  203 
 204 
Results 205 
Study population.  206 
A total of 1631 neonates and infants from 15 studies were included (Table 1). Their PMA 207 
and current weight (CW), expressed as mean (standard deviation) were 33.3 (5.7) weeks 208 
and 1785 (1127) grams, respectively. Overview of the individual PK trials is presented in 209 
Table 2. We refer to the original studies for additional factual information.14-26 210 
 211 
Population PK analysis 212 
Model building 213 
A total of 4894 concentrations from 1631 patients were included in the population 214 
analysis. A two-compartment model with ﬁrst-order elimination best fitted the data; both 215 
the OFV and the residual variability were lower than with a one-compartment model. 216 
Covariate analysis 217 
Allowing separate estimates for each analytical method in the residual variability caused 218 
a significant drop in the OFV of 113.5 units. Body weight was the most important clinical 219 
covariate following a systematic covariate analysis, associated with a drop in the OFV of 220 
3367.1 units after incorporating it into the basic model using estimated allometric 221 
coefficients for CL, V1 and V2. A further decrease in the OFV of 244.5 units was achieved 222 
by including PMA on CL and serum creatinine concentrations gave a further reduction 223 
(ΔOFV 1087.9 units). The model was further improved (ΔOFV 65.5 units) by introducing 224 
a conversion factor between the Jaffé and enzymatic assay methods for creatinine. 225 
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Ethnicity (Malaysian patients) was identified as a sixth covariate (ΔOFV 302.1 units) on 226 
CL. The final model had the following structure: 227 
CL = 0.0680 × (CW/1350)0.863 × RM × RF × FJaffé-Enzymatic × Frace 228 
where CW is current weight, RM reflects renal maturation and RF reflects renal function. 229 
The population PK parameters of the final model are presented in Table 3.  230 
Model evaluation 231 
Model diagnostics showed acceptable goodness-of-fit for the final model. Predictions 232 
were unbiased and no trends were observed in the diagnostic plots of CWRES versus 233 
time. The NPDE distribution and histogram were consistent with the theoretical N (0, 1) 234 
distribution and density, indicating a good fit of the model to the individual data (Figure 235 
1). The mean and variance of the NPDEs were 0.09 and 0.98, respectively. Visual 236 
predictive checks (VPCs) of the final model for all neonates and in subgroups of neonates 237 
<29 weeks (L), 29-35 weeks (M) and >35 weeks (H) are shown in Fig. 2 (A and B). The 238 
plots confirm that the average predicted concentrations matched the observed 239 
concentrations and that the variability was well estimated in the 3 subgroups.  240 
In addition, the median PK parameter estimates resulting from the bootstrap procedure 241 
closely agreed with the respective values from the final population model, indicating that 242 
the final model was stable (Table 3).  243 
Dosing optimisation. 244 
Dosing optimisation was conducted in the Caucasian population. Monte Carlo simulations 245 
were performed to evaluate different mg/kg dosing regimens for the three neonatal 246 
groups.  247 
With the standard vancomycin dosing regimen at steady-state, the percentage of 248 
neonates reaching the target AUCss0-24 of ≥400 mg*h/ was 74.0% and the percentage 249 
exposed to an AUCss0-24 above 700 mg*h/L was 23.0% when considering all age groups.  250 
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When considering only neonates <29 weeks PMA, the corresponding values fell to 27.7% 251 
and 1.1% respectively (Table 4).  252 
With a loading dose of 25 mg/kg followed by the optimal maintenance dose of 15 mg/kg, 253 
either ‘q12h’ if ≤35 weeks PMA or ‘q8h’ if >35 weeks PMA, the percentage of neonates 254 
reaching the target AUCss0-24 of 400 mg*h/L was 89.3% while the percentage exposed to 255 
an AUCss24h over 700 mg*h/L was 33.3% when considering all age groups. When 256 
considering only neonates <29 weeks PMA, the corresponding values increased to 95.0% 257 
and 45.5% respectively (Table 5). The target attainment rate on the first day of treatment 258 
increased from 42.6% with the standard regimen to 88.9% with the loading dose strategy. 259 
 260 
Discussion 261 
To the best of our knowledge, this is the largest meta-analysis that has assessed the 262 
population PK of vancomycin in neonates and young infants aged less than 3 months. 263 
The analysis has combined vancomycin concentrations linked to key demographic and 264 
biological covariates from 15 pharmacokinetic studies conducted in 7 different countries. 265 
Monte-Carlo simulations showed that the current dosage regimen was not suitable for the 266 
treatment of staphylococcal infection and that the optimal vancomycin dosing regimen 267 
should include a loading dose of 25 mg/kg for all neonates, irrespective of their PMA, 268 
followed by a maintenance dose adapted to their PMA. 269 
Although widely used for many years, important questions remain on how to optimise 270 
vancomycin dosing in neonates.2,8,9 In the absence of prospective evaluation, most 271 
neonatal units have developed local dosing recommendations, resulting in variable 272 
exposures that may lead to poor efficacy, induction of resistance or toxicity3 273 
Consequently, vancomycin dosage regimens adapted to neonates require harmonisation, 274 
taking into account the impact of developmental pharmacology on disposition and PK 275 
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parameters from very preterm neonates through term neonates to older children.27 This 276 
issue is central and initiatives from both the FDA and EMA are currently being undertaken 277 
to revise vancomycin dosing.28,29 278 
Drug pharmacokinetics and dynamics need to be linked to explicative individual 279 
characteristics either constitutional (age, weight, genetics, etc.) or environmental 280 
(pathology, drug interactions, etc.). In this context, population modelling allows 281 
assessment and quantification of sources of variability in drug exposure and response in 282 
the target population, even under sparse sampling conditions 30-32  The present study has 283 
confirmed the impact of serum creatinine and vancomycin assay methods as predictors 284 
of vancomycin concentrations in neonates.33,34 Additional covariates, such as 285 
ventilation,35 co-administered drugs (e.g. aminoglycosides or ibuprofen), ECMO,37 whole 286 
body cooling,38 as well as centre or country dependent effects linked to ethnic, 287 
environmental and nutritional differences, were not explored in the current study, as they 288 
were not available in all data sets. However, it is recognised that they may also contribute 289 
to PK variability in neonates. 290 
Model-based approaches to characterise drug PK/PD have been recommended as 291 
powerful tools for overcoming the practical and ethical challenges associated with dose 292 
selection for neonatal indications.39,40  For vancomycin, a model tailored dose had already 293 
been demonstrated to increase substantially the target attainment rate of vancomycin in 294 
treated neonates.10 However, there were few neonates less than 29 weeks gestational 295 
age in that study and centre-effects could not be eliminated.  These limitations were 296 
addressed in the present PK meta-analysis, which was conducted by pooling 4894 297 
vancomycin concentrations from 1631 neonates. Although robust parameter estimates 298 
were obtained with this strategy, different strategies may be necessary when data are 299 
heterogenous.41  300 
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For vancomycin, exposure, measured by AUC0-24, is the PK/PD parameter influencing 301 
efficacy and emergence of resistance,42-44 but also influencing toxicity. Nephrotoxicity is 302 
a multifactorial, well-identified risk of high vancomycin exposure and high trough 303 
concentrations.45 AUC0-24 or corresponding trough levels can vary widely and 304 
independently, since the trough depends on both the daily dose and the frequency of 305 
administration, whereas AUC0-24 only depends on the daily dose. Consequently, in the 306 
present study, simulations were performed to evaluate the current dosage regimen13 and 307 
to optimize efficacy by determining the target attainment rate and exposure to vancomycin 308 
measured by the AUC0-24h. A target AUC0-24h of at least 400 mg*h/L was selected as an 309 
AUC0-24/MIC ratio of 400 has been associated with favourable treatment outcomes in 310 
adults, assuming that bacterial strains have a vancomycin MIC ≤1 mg/L.43,46 Simulations 311 
of the current dosage recommendation (see table 5) were performed after the first dose 312 
and at steady-state. Our results showed that the current daily dose was too low for all 313 
neonatal age groups but particularly for neonates <29 weeks, as less than 30% of 314 
neonates reached the steady-state target. As a loading dose strategy is recommended in 315 
adult settings in order to reduce the time needed to reach the target AUC0-24 47,48 316 
simulations were then performed with a loading dose and optimal maintenance doses in 317 
all age groups, based on weight and PMA. Increasing the maintenance dose to 15 mg/kg 318 
‘q12h’ instead of ‘q24h’ was also tested in the group  <29 PMA weeks to optimise dosage. 319 
These modifications led to an increase in the target attainment rate after the first dose 320 
and at steady-state in all age groups.  321 
Nephrotoxicity is a recognized side-effect of vancomycin treatment, although its safety 322 
profile is considered favorable. The risk of nephrotoxicity primarily increases with high 323 
vancomycin exposure and duration of administration.45,49 In studies in adults and 324 
children,45 reported incidence varied widely, from 5% to 43%, occurrence increased with 325 
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longer durations of administration with a range of 4.3 to 17 days and nephrotoxicity was 326 
reversible in the majority of cases. In neonates, most studies were not sufficiently 327 
powered to detect nephrotoxicity and, when reported, renal impairment was frequently 328 
associated with concomitant administration of nephrotoxic drugs.50 329 
Therefore, optimising exposure while reducing duration of administration would maximise 330 
clinical efficacy while minimising toxicity and selection of resistance.  331 
The upper AUC24h limit remains a matter of debate. “Usual” AUC24h values of 700 or 800 332 
mg*h/L have been used in both adults 46,51,52 and children,48 however, more extreme 333 
values have also been reported, with breakpoints for nephrotoxicity of <600 or >1300 334 
mg*h/L.51,53 In the absence of specific neonatal data, a value of 700 mg*h/L was used in 335 
the present study. With our simulated dosage regimen, 89% of neonates reached the 336 
predetermined AUCss-24h target and 21.0% had an AUCss-24h, over 800 mg*h/L; this was 337 
slightly higher that the percentage expected with the dosing regimen that is currently 338 
used. Additional TDM is necessary to individualise therapy for patients at risk of high 339 
exposure rates. 340 
The simulated drug regimens presented here in the different neonatal age groups 341 
resulted in higher percentage of patients who would reach the target for efficacy but 342 
also higher percentage of patients who would have vancomycin concentrations over the 343 
nephrotoxicity threshold of 15-20 mg/L, reported both in adults and children. 24,54,55 This 344 
potential higher risk of nephrotoxicity requires further evaluation, but in our recent 345 
patient-tailored vancomycin dose study in 190 neonates, no patient developed 346 
nephrotoxicity after model-based TDM although the AUC0-24h reached 1200 mg·h/L in 347 
some patients.10  348 
The simulated vancomycin regimens were developed as the pre-clinical component of 349 
the FP7 NeoVanc programme. As our final objective is to maximise clinical efficacy and 350 
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minimise toxicity and selection of resistance by increasing exposure and reducing 351 
length of treatment, our data are now being taken forward in a RCT of the optimised 352 
regimen in which the duration of vancomycin therapy is reduced to 5 days, compared to 353 
a standard dosing regimen and administration for 10 days. The NeoVanc RCT trial was 354 
evaluated by experts at the EC, a pediatric Investigation Plan was validated by EMA 355 
and regulatory authorities and a DSMD closely monitors patients and data. Due to 356 
multifactorial variability in vancomycin disposition, drug monitoring is being performed 357 
in patients included in the two arms to further guide dosing56 , although a trough level is 358 
not a very good predictor of AUC24h.57,58 Our RCT will also provide information on 359 
additional factors specific to neonates that may contribute to toxicity, including 360 
hypovolemia, concurrent nephrotoxic drug use. 361 
  362 
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 565 
Figure 1: Goodness-of-fit plots: A) Population predicted (PRED) versus observed 566 
concentrations (DV); B) Individual predicted (IPRED) versus DV; C) Conditional weighted 567 
residuals (CWRES) versus time; D) CWRES) versus PRED, Normalised prediction 568 
distribution errors: E) QQ-plot of the distribution of the Normalised Prediction Distribution 569 
Errors (NPDE) versus the theoretical N (0,1) distribution; F) Histogram of the distribution 570 
of the NPDE, with the density of the standard Gaussian distribution overlaid. 571 
 572 
Figure 2: Validation of the model by use of a visual predictive check (VPC) Visual 573 
predictive check after continuous (CVA: 2A) and intermittent (IVA) vancomycin 574 
administration.  Comparison of the 5th (bottom dashed line), 50th (solid line), and 95th (top 575 
dashed line) percentiles obtained from 1,000 simulations and the observed data (circles) 576 
for vancomycin concentrations in premature neonates <29 weeks (L), 29-35 weeks (M) 577 
and >35 weeks (H).  Open circles represents individual observed concentrations. 578 
 579 
 580 
 581 
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 583 
 584 
 585 
 586 
 587 
Table 1 588 
 589 
 590 
Demographic characteristics of the 1631 neonates and infants included 591 
 592 
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 Number (%) Mean (SD) Median (min-max) 
Patients 1631   
Race 
1463 (89.7) 
Caucasian 
116 (7.1) Malaysian 
52 (3.2) Japanese 
  
GA (weeks) 
 
 31.2 (5.0) 30.0 (22.3 - 42.1 
PMA (weeks)  33.3 (5.7) 32.0 (23.3 - 52.4) 
 
PNA (days)  16 (15) 11 (1 - 90) 
 
Current weight (g)  1785 (1127) 1350 (415 - 11370) 
 
Serum creatinine 
concentration (μmol/L) 
 
 59.2 (32.0) 53.9 (6.2 – 353.6) 
 
Vancomycin 
treatment 
   
Continuous infusion 295 (18.1)   
Intermittent infusion 1336 (81.9)   
 593 
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Table 2 595 
Presentation of the studies included in the vancomycin meta-analysis 596 
Study 
 
N of 
patients 
(N=1631) 
PK study 
Adminis
-tration 
 
Location 
Creatinin
e 
method 
Vancomyci 
n 
method 
Ref 
 
1 59 Single center IVA Glasgow, 
UK 
Jaffé FPIA 14 
2 294 Multi centers 
(4)* 
IVA San 
Diego, US 
Jaffé EMIT and 
FPIA 
15 
3 35 Single center IVA Glasgow, 
UK 
Jaffé FPIA 16 
4 210 Single center IVA Leuven, 
Belgium 
Jaffé PETINIA 17 
5 116 Single center IVA Kuala 
Lumpur, 
Malaysia 
Jaffé FPIA 18 
6 66 Single center CVA Marseille, 
France 
Enzymatic EMIT 19 
7 61 Single center CVA Marseille, 
France 
Enzymatic EMIT 20 
8 125 Single center IVA Memphis, 
US 
Enzymatic EMIT 21 
9 55 Single center CVA Glasgow, 
UK 
Enzymatic CMIA 22 
10 78 Single center IVA Paris, 
France 
Enzymatic EMIT AND 
FPIA 
23 
11 113 Multi centers 
(3)* 
CVA Paris, 
France 
Enzymatic PETINIA 
AND FPIA 
24 
12 199 Single center IVA Leuven, 
Belgium 
Enzymatic PETINIA 
AND FPIA 
25 
15 68 Single center IVA Tartu, 
Estonia 
Enzymatic FPIA 26 
13 52 Single center IVA Tokyo, 
Japan 
Enzymatic CLIA NP 
14 100 Single center IVA Valencia, 
Spain 
Enzymatic FPIA NP 
 597 
*: Number of centers was given for multi centers study 598 
NP: not published; CVA: Continuous intravenous Vancomycin Infusion; IVA: Intermittent 599 
intravenous Vancomycin infusion; PETINIA: particle enhanced turbidimetric inhibition 600 
immunoassay FPIA: fluorescence polarization immunoassay method; EMIT: enzyme-601 
multiplied immunoassay method; CMIA: chemiluminescent microparticle immunoassay; 602 
CLIA: chemiluminescent immunoassay; CREA: serum creatinine concentration in 603 
μmol/L; PMA: postmenstrual age in weeks.  604 
 27 
In our population, 1350 gram, 32 weeks and 52 μmol/L are the median current weight 605 
(day of the study), postmenstrual age, and serum creatinine concentration values, 606 
respectively. 607 
  608 
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Table 3: Population pharmacokinetic parameters of vancomycin and Bootstrap 609 
results (n = 500) 610 
 611 
Parameters Full data set Bootstrap 
 Final RSE(%) Median 2.5th - 97.5th 
Central volume of distribution V1 (L)     
V1 = 1 x (CW/1350)2     
1 0.728 1.5 0.714 0.414 – 0.742 
2 1.13 3.0 1.12 0.596 – 1.200 
Peripheral volume of distribution V2 (L)     
V2 = 3 x (CW/1350)4     
3 0.358 11.1 0.335 0.185 – 0.474 
4 1.15 14.9 1.25 0.75 – 1.93 
Intercompartmental clearance (Q) (L/h)     
Q = 5 x (CW/1350)     
5 0.030
1 
12.5 0.0361 0.0248 – 1.190 
Clearance (L/h)     
CL = 6 x (CW/1350)7 x RM x RF x FJaffé-
Enzymatic 
    
6 0.068
0 
1.3 0.0686 0.0664 – 0.0717 
7 0.863 5.3 0.895 0.787 – 0.968 
RM = (PMA/32)8     
8 0.544 30.3 0.544 0.143 – 0.816 
RF = (1/ FJaffé-Enzymatic x CREA/54)9     
9 0.666 3.6 0.655 0.598 – 0.718 
FJaffé-Enzymatic     
10 0.720 2.8 0.716 0.682 – 0.756 
FRace     
11 0.724 2.8 0.710 0.646 – 0.757 
Inter-individual variability (%)     
V1 17.5 25.6 14.1 1.7 – 23.0 
V2 102.5 25 80.3 19.2 – 132.8 
CL 18.2 21.6 15.2 2.2 – 21.0 
Inter-occasion variability (%)     
CL 19.1 20.1 16.7 2.4 – 22.7 
Residual proportional (%)     
FPIA 22.2 4.8 22.2 19.9 – 24.2 
EMIT 20.9 7.3 21.1 18.0 – 24.0 
PENTINIA 25.1 5.6 24.7 21.7 – 27.8 
CMIA 10.7 21.2 10.6 5.7 – 14.2 
CLIA 38.3 25.8 39.2 19.6 – 58.5 
Residual additive (mg/L)     
FPIA 1.57 7.7 1.63 1.32 – 1.99 
EMIT 1.53 16.7 1.54 0.94 – 2.08 
PENTINIA 1.01 19.6 1.06 0.59 – 1.65 
CMIA 2.02 26.1 2.07 0.71 – 2.78 
CLIA 3.30 28.7 3.26 0.723 – 4.97  
 612 
 613 
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Table 4: Monte Carlo simulations of vancomycin standard dose regimen* 615 
 616 
PMA (weeks) <29 29 - 35 >35 Total 
Number of patients 335 618 510 1463# 
Standard dose regimen (mg/kg) 15 OD 15 BID 15 TID  
First day     
AUC0-24h median (mg*h/L) 246 378 495 385 
AUC0-24h 5th-95th (mg*h/L) 163-356 264-523 332-725 203-638 
Target attainment rate (%) 1.5 39.0 81.0 45.1 
AUC0-24h 400 - 700mg*h/L (%) 1.5 38.9 74.0 42.6 
AUC0-24h >700mg*h/L (%) 0 0.1 7.0 2.5 
AUC0-24h >800mg*h/L (%) 0 0 2.0 0.7 
Cmin24h median (mg/L) 3.8 9.0 14.3 9.0 
Cmin24h 5th-95th  (mg/L) 0.2–8.7 2.9–18.4 4.8–30.8 1.6–24.0 
Cmin24h >20mg/L (%) 0 3.4 24.2 9.9 
Steady state     
AUC0-24h median (mg*h/L) 338 536 654 520 
AUC0-24h 5th-95th (mg*h/L) 203-547 323-893 368-1276 259-1028 
Target attainment rate (%) 27.7 84.3 91.9 74.0 
AUC0-24h 400 - 700mg*h/L (%) 26.6 65.5 49.4 51.0 
AUC0-24h >700mg*h/L (%) 1.1 18.7 42.5 23.0 
AUC0-24h >800mg*h/L (%) 0.5 10.0 29.6 14.7 
Cmin24h median (mg/L) 6.0 12.3 17.2 11.9 
Cmin24h 5th-95th  (mg/L) 1.1–14.7 4.1–28.3 5.6–46.0 2.8–34.4 
Cmin24h >20 mg/L (%) 12.8 17.6 40.0 21.7 
 617 
* as indicated in the Blue Book (12), 618 
# number of Caucasian patients, 619 
AUC0-24h : 24h Area Under the Curve at the first day, 620 
Cmin24h : trough level at the first day 621 
AUCss-24h : 24h Area Under the Curve at steady-state, 622 
Cminss-24h: trough level at steady-state  623 
 30 
Table 5: Monte Carlo simulation of vancomycin dosage regimen with a loading 624 
dose 25 mg/kg following by optimal maintenance dose 625 
 626 
PMA (weeks) <29 29 - 35 >35 Total 
Number of patients 335 618 510 1463 
Loading dose (mg/kg) 25 25 25  
Optimal maintenance dose (mg/kg) 15 BID 15 BID 15 TID  
First day     
AUC0-24h median (mg*h/L) 559 492 596 539 
AUC0-24h 5th-95th (mg*h/L) 384-787 336-692 426-820 358-812 
Target attainment rate (%) 87.8 83.0 93.2 88.9 
AUC0-24h 400 - 700mg*h/L (%) 74.0 78.6 67.5 74.7 
AUC0-24h >700mg*h/L (%) 13.7 4.4 25.7 14.2 
AUC0-24h >800mg*h/L (%) 4.1 1.0 12.0 5.6 
Cmin24h median (mg/L) 14.4 10.7 15.5 13 
Cmin24h 5th-95th  (mg/L) 5.3–28.0 3.6–22.5 5.2–34.7 4.3–29.0 
Cmin24h >20mg/L (%) 21.2 8.9 31.3 19.8 
Steady state     
AUC0-24h median (mg*h/L) 677 529 656 600 
AUC0-24h 5th-95th (mg*h/L) 401-1102 325-883 368-1293 348-1093 
Target attainment rate (%) 95.0 83.5 92.5 89.3 
AUC0-24h 400 - 700mg*h/L (%) 49.5 65.0 49.4 56.0 
AUC0-24h >700mg*h/L (%) 45.5 17.6 43.1 33.3 
AUC0-24h >800mg*h/L (%) 28.9 9.0 30.3 21.0 
Cmin24h median (mg/L) 17.5 12.2 17.5 15 
Cmin24h 5th-95th  (mg/L) 6.5–38.0 4.0–28.5 5.6–46.1 4.9–37.6 
Cmin24h >20 mg/L (%) 39.3 17.6 41.5 30.9 
 627 
AUC0-24h : 24h Area Under the Curve at the first day, 628 
Cmin24h : trough level at the first day 629 
AUCss-24h : 24h Area Under the Curve at steady-state, 630 
Cminss-24h: trough level at steady-state  631 
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